Cost-effectiveness analysis of tandem mass spectrometry compared to fluorescence analysis for screening neonatal genetic metabolic diseases.

IF 3 3区医学 Q2 HEALTH CARE SCIENCES & SERVICES BMC Health Services Research Pub Date : 2025-02-18 DOI:10.1186/s12913-025-12419-z

Shanyan Zhou, Dunming Xiao, Zhen Huang, Junling Weng, Bingxing Luo, Yingyao Chen

{"title":"Cost-effectiveness analysis of tandem mass spectrometry compared to fluorescence analysis for screening neonatal genetic metabolic diseases.","authors":"Shanyan Zhou, Dunming Xiao, Zhen Huang, Junling Weng, Bingxing Luo, Yingyao Chen","doi":"10.1186/s12913-025-12419-z","DOIUrl":null,"url":null,"abstract":"Objective: To compare the cost-effectiveness of tandem mass spectrometry (MS/MS) screening for neonatal inherited metabolic diseases (IMDs) with fluorescence analysis (FA) screening for neonatal inherited metabolic diseases (IMDs) and provide evidence for promoting MS/MS in China.Methods: An Excel-based decision tree model was constructed to evaluate the cost-effectiveness of MS/MS versus FA screening from a societal perspective. The model simulated the screening pathway, prevention, and treatment of IMDs, adjusted to 2023 price levels. Health outcomes were measured in quality-adjusted life years (QALYs), with a 3% annual discount rate applied. The willingness-to-pay (WTP) threshold was set at one times the per-capita GDP of China in 2023.Results: MS/MS screening was more costly (CNY 1,121,637; USD 158,423 vs. CNY 380,276; USD 53,711) but more effective (16.47 QALYs vs. 5.93 QALYs) than FA screening. The incremental cost-effectiveness ratio (ICER) was CNY 70,286 (USD 9,927) per QALY, below the WTP threshold. The benefit-cost ratio (BCR) was 1:3.94.Conclusion: While MS/MS screening incurs higher costs, it achieves significantly greater QALY gains and demonstrates favorable cost-effectiveness and economic benefits. MS/MS screening should be actively promoted for neonatal IMDs in China.","PeriodicalId":9012,"journal":{"name":"BMC Health Services Research","volume":"25 1","pages":"272"},"PeriodicalIF":3.0000,"publicationDate":"2025-02-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11837304/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"BMC Health Services Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s12913-025-12419-z","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEALTH CARE SCIENCES & SERVICES","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: To compare the cost-effectiveness of tandem mass spectrometry (MS/MS) screening for neonatal inherited metabolic diseases (IMDs) with fluorescence analysis (FA) screening for neonatal inherited metabolic diseases (IMDs) and provide evidence for promoting MS/MS in China.

Methods: An Excel-based decision tree model was constructed to evaluate the cost-effectiveness of MS/MS versus FA screening from a societal perspective. The model simulated the screening pathway, prevention, and treatment of IMDs, adjusted to 2023 price levels. Health outcomes were measured in quality-adjusted life years (QALYs), with a 3% annual discount rate applied. The willingness-to-pay (WTP) threshold was set at one times the per-capita GDP of China in 2023.

Results: MS/MS screening was more costly (CNY 1,121,637; USD 158,423 vs. CNY 380,276; USD 53,711) but more effective (16.47 QALYs vs. 5.93 QALYs) than FA screening. The incremental cost-effectiveness ratio (ICER) was CNY 70,286 (USD 9,927) per QALY, below the WTP threshold. The benefit-cost ratio (BCR) was 1:3.94.

Conclusion: While MS/MS screening incurs higher costs, it achieves significantly greater QALY gains and demonstrates favorable cost-effectiveness and economic benefits. MS/MS screening should be actively promoted for neonatal IMDs in China.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

串联质谱与荧光分析筛查新生儿遗传代谢疾病的成本-效果分析

目的：比较串联质谱（MS/MS）筛查新生儿遗传代谢性疾病（IMDs）与荧光分析（FA）筛查新生儿遗传代谢性疾病（IMDs）的成本-效果，为在中国推广MS/MS提供依据。方法：构建基于excel的决策树模型，从社会角度评价MS/MS与FA筛选的成本-效果。该模型模拟了imd的筛选途径、预防和治疗，调整到2023年的价格水平。以质量调整生命年（QALYs）衡量健康结果，采用3%的年贴现率。2023年，支付意愿（WTP）门槛设定为中国人均GDP的1倍。结果：MS/MS筛查成本较高(1,121,637元；158,423美元对380,276元；53,711美元)，但比FA筛查更有效（16.47 QALYs对5.93 QALYs）。增量成本效益比（ICER）为每个QALY 70,286元（9,927美元），低于WTP阈值。效益成本比（BCR）为1:3.94。结论：MS/MS筛查成本较高，但QALY收益明显较高，具有较好的成本效益和经济效益。在中国应积极推广MS/MS筛查新生儿imd。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

BMC Health Services Research 医学-卫生保健

CiteScore

4.40

自引率

7.10%

发文量

1372

审稿时长

6 months

期刊介绍： BMC Health Services Research is an open access, peer-reviewed journal that considers articles on all aspects of health services research, including delivery of care, management of health services, assessment of healthcare needs, measurement of outcomes, allocation of healthcare resources, evaluation of different health markets and health services organizations, international comparative analysis of health systems, health economics and the impact of health policies and regulations.